Coherus Shares Are Trading Higher As Toripalimab Shows Survival Benefit In Late-Stage Esophageal Cancer Study

by Vandana Singh, Benzinga Editor

April 23, 2021 10:11 AM | 1 min read |

Coherus BioSciences Inc's CHRS partner Junshi Biosciences reported interim analysis from JUPITER-06 Phase 3 trial evaluating toripalimab in combination with paclitaxel/cisplatin chemo as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC).
Independent Data Monitoring Committee has determined that toripalimab-paclitaxel/cisplatin combo has achieved the pre-specified primary endpoints of progression-free survival (PFS) and overall survival (OS).
Interim data showed toripalimab combo therapy significantly prolonged the PFS and OS, compared with paclitaxel/cisplatin alone.
Data from the study are expected later this year.
Earlier in 2021, Coherus in-licensed rights to develop and commercialize toripalimab in the United States and Canada.
Price Action: CHRS shares are up 0.5% at $14.71 on the last check Friday.

Posted In:

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.